NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum

Experimental Neurology

Volumn 161, Issue 2, 2000, Pages 638-646

  Zeevalk, Gail D ^a   Manzino, Lawrence ^a   Sonsalla, Patricia K ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Basal ganglia; Glutamate receptors; Malonate; Midbrain; Mitochondria; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; DIZOCILPINE; DOPAMINE; MALONIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENERGY METABOLISM; MALE; MITOCHONDRIAL RESPIRATION; NERVE CELL LESION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0034097606     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7283     Document Type: Article

References (42)

1. Albers D. S., Weiss S. W., Iadorola M. J., Standaert D. G. Immunohistochemical localization of N-methyl-d-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepriopionate receptor subunits in the substantia nigra pars compacta of the rat. Neuroscience. 89:1998;209-220.
2. Albers D. S., Zeevalk G. D., Sonsalla P. K. Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res. 718:1996;217-220.
3. Beal M. F., Brouillet E., Jenkins B., Henshaw R., Rosen B., Hyman B. T. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61:1993;1147-1150.
4. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J., Martin J. B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
5. Benecke R., Strumper P., Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain. 116:1993;1451-1463.
6. Bernard V., Bolam J. P. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: Co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur. J. Neurosci. 10:1998;3721-3736.
7. Blandini F., Porter R. H. P., Greenamyre J. T. Glutamate and Parkinson's disease. Mol. Neurobiol. 12:1996;73-94.
8. Bouyer J. J., Park D. H., Joh T. J., Pickel V. M. Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum. Brain Res. 302:1984;267-275.
9. Buchan A., Pulsinelli W. Are the neuroprotective effects of MK-801 mediated by hypothermia. Stroke. 20:1989;148.
10. Carter C. J., L'Heureux R., Scatton B. Differential control by N-methyl-d-aspartate and kainate of striatal dopamine release in vivo: A trans-striatal dialysis study. J. Neurochem. 51:1988;462-468.
11. Cheramy A., Barbeito L., Godeheu G., Desce J. M., Pittaluga A., Galli T., Artaud F., Glowinski J. Respective contributions of neuronal activity and presynaptic mechanisms in the control of the in vivo release of dopamine. J. Neural Transm. 29:1990;183-193.
12. Chergui K., Charlety J., Akaoka H., Saunier C. F., Brunet J.-L., Buda M., Scensson T. H., Chouvet G. Tonic activation of NMDA receptors causes spontateous burst discharge of rat midbrain dopamine neurons in vivo. Eur. J. Neurosci. 5:1993;137-144.
13. Christoffersen C. L., Meltzer L. T. Evidence for N-methyl-d-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: Possible preferential role for N-methyl-d-aspartate receptors. Neuroscience. 67:1995;373-381.
14. Coyle J. T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature. 263:1976;244-246.
15. Gonon F. G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience. 24:1988;19-28.
16. Greene J. G., Greenamyre J. T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48:1996;613-634.
17. Greene J. G., Porter R. H. P., Eller R. V., Greenamyre J. T. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J. Neurochem. 61:1993;1151-1154.
18. Haas R. H., Nasirian F., Nakano K., Ward D., Pay R. N., Hill R., Shults C. W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37:1995;714-722.
19. Henshaw R., Jenkins B. G., Schulz J. B., Ferrante R. J., Kowall N. W., Rosen B. R., Beal M. F. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res. 647:1994;161-166.
20. Keefe K. A., Zigmond M. J., Abercrombie E. D. In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acids. J. Neural. Transm. 91:1993;223-240.
21. Konig J. F. R., Klippel R. A. The Rat Brain: A Stereotaxic Atlas of the Forebrain. 1967;Krieger, Huntington.
22. Korf J., Venema K. Amino acids in the substantia nigra of rats with striatal lesions produced by kainic acid. J. Neurochem. 40:1983;1171-1173.
23. Kupsch A., Loschmann P. A., Sauer H. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res. 592:1992;74-83.
24. Mackenize G. M., Greenamyre J. T. A novel model of slowly progressive Parkinson's disease. Soc. Neurosci. 24:1998;1498.
25. Marey-Semper I., Gelman M., Levi-Strauss M. L. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur. J. Neurosci. 5:1993;1029-1034.
26. McGeer E. G., McGeer P. L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injection of glutamic and kainic acids. Nature (Lond.). 263:1976;517-519.
27. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163:1989;1450-1455.
28. Moghaddam B., Gruen R. J., Roth R. H., Bunney B. S., Adams R. N. Effect of l-glutamate on the release of striatal dopamine: in vivo dialysis and electrochemical studies. Brain Res. 518:1990;55-60.
29. Nicklas W. J., Vyas I., Heikkila R. E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
30. Olney J. W. Neurotoxicity of excitatory amino acids. McGeer E. G., Olney J. W., McGeer P. L. Kainic Acid as a Tool in Neurobiology. 1978;201-218 Raven Press, New York.
31. Parker W. D., Boyson S. J., Parks J. K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-733.
32. Pickel V. M., Beckley S. C., Joh T. J., Reis D. J. Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res. 225:1981;373-385.
33. Shoffner J. M., Watts R. L., Juncos J. L., Torroni A., Wallace D. C. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. 30:1991;332-339.
34. Siesjo B. K., Memezawa H., Smith M. L. Neurocytotoxicity: Pharmacological implications. Fundam. Clin. Pharmacol. 5:1991;755-767.
35. Sonsalla P. K., Manzino L., Sinton C. M., Liang C.-L., German D. C., Zeevalk G. D. Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra. Brain Res. 773:1997;223-226.
36. Sonsalla P. K., Riordan D. V., Heikkila R. E. Protection by competitive and noncompetitive NMDA receptor antagonists against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256:1991;506-512.
37. Sonsalla P. K., Zeevalk G. D., Manzino L., Giovanni A., Nicklas W. J. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J. Neurochem. 58:1992;1979-1982.
38. + neurotoxicity by N-methyl-d-aspartate antagonists. Nature. 349:1991;414-420.
39. Zeevalk G. D., Davis N., Hyndman A. G., Nicklas W. J. Origins of the extracellular glutamate released during total metabolic blockade in the immature retina. J. Neurochem. 71:1998;2373-2381.
40. Zeevalk G. D., Derr-Yellin E., Nicklas W. J. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid: Relation between NMDA receptor mediated damage and extracellular glutamate. J. Pharmacol. Exp. Ther. 275:1995;1124-1130.
41. Zeevalk G. D., Manzino L., Hoppe J., Sonsalla P. K. In vivo vulnerability of dopamine neurons to inhibition of energy metabolism. Eur. J. Pharmacol. 320:1997;111-119.
42. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F., Corsini G. V. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in primates. J. Neurochem. 59:1992;733-739.